eXoZymes Announces Pricing of Public Stock and Warrant Offering

eXoZymes Inc. has officially set the pricing for its latest public offering, which includes a combination of common stock shares and warrants. The biotechnology firm projects that this initiative will bring in approximately $5.33 million in gross proceeds before factoring in underwriting discounts and other expenses associated with the offering. According to Seeking Alpha, the offering consists of nearly 2.67 million units. Each unit is structured to include one share of the company's common stock and one warrant. These warrants will allow purchasers to acquire an additional share of common stock at a later date. The price per unit for the offering has been established at $2.00. The warrants bundled with each share are immediately exercisable upon issuance. The exercise price for these warrants is also set at $2.00 per share, aligning with the initial unit price. Investors holding these warrants will have a five-year window to exercise them, commencing from the date of issuance. This offers a substantial period for warrant holders to decide on future share purchases, potentially benefiting from any upward movement in the company's stock price. The offering is slated to close around May 1, 2020, subject to the customary closing conditions. This timeline indicates the finalization of the transaction and the transfer of funds to eXoZymes. National Securities Corporation, a division of National Holdings Corporation, is acting as the sole book-running manager for this public offering. Their role involves managing the sales process and coordinating with investors to ensure the successful completion of the offering. This capital infusion is expected to bolster eXoZymes' financial position, potentially funding ongoing research and development, clinical trials, or general corporate purposes. The decision to include warrants often serves to sweeten the deal for investors, providing an additional incentive beyond the initial stock purchase itself.